Emmaus Life Sciences Reports 2021 Financial Results and Provides Business Update

Provided By PR Newswire

Last update: Mar 31, 2022

TORRANCE, Calif., March 31, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the year ended December 31, 2021 and an update on recent activities.